Cannabis is evidence-based for cancer symptom management — pain, nausea, appetite, and sleep — while direct anti-tumor evidence remains preclinical.
Cancer affects 1.9 million Americans annually. Cannabis has strong evidence for managing cancer-related symptoms — pain, chemotherapy-induced nausea, appetite loss, and sleep disruption — and is one of the most common reasons cancer patients use medical cannabis. Preclinical evidence for direct anti-tumor activity exists for several cannabinoids, but no human trial has established anti-tumor efficacy.
18 million cancer survivors
Americans Affected
1.9 million new diagnoses annually in the U.S.
Prevalence
2
Key Studies
3
Cannabinoids Reviewed
Cannabis has strong evidence for cancer symptom management. For pain: nabiximols RCT showed significant improvement in opioid-refractory cancer pain. For CINV: dronabinol is FDA-approved. For appetite: dronabinol is FDA-approved for cancer-related anorexia. For sleep and anxiety: CBD has consistent evidence. Direct anti-tumor evidence is preclinical only.
Cannabis manages cancer symptoms through well-characterized mechanisms: CB1 analgesia for pain, CB1 antiemesis for CINV, CB1 appetite stimulation for cachexia, and CBD anxiolysis for cancer-related anxiety. These are the evidence-based applications.
Multiple cannabinoids have demonstrated anti-tumor activity in cell and animal models: inducing apoptosis (programmed cell death), inhibiting angiogenesis (tumor blood vessel formation), and reducing tumor invasion and metastasis. These effects have been demonstrated for THC, CBD, and CBG in various cancer cell lines.
Cancer pain often requires opioids. Cannabis's opioid-sparing effect — demonstrated in the nabiximols RCT and the 2026 cohort study — allows opioid dose reduction, reducing opioid-related adverse effects in cancer patients.
Dronabinol (synthetic THC) FDA-approved for CINV and cancer-related anorexia. Nabiximols (THC:CBD) has RCT evidence for opioid-refractory cancer pain.
CBD reduces cancer-related anxiety, improves sleep, and has opioid-sparing analgesic effects. No anti-tumor evidence in humans.
CBG has demonstrated anti-tumor activity in colorectal cancer cell lines. Preclinical only — no human evidence.
Nabiximols for Opioid-Treated Cancer Pain
Low-dose nabiximols significantly improved pain in opioid-treated cancer patients with inadequate control (p=0.014).
Medical Cannabis and Opioid Use: 500,000-Patient Cohort
31% opioid MME reduction in cancer pain patients enrolled in medical cannabis programs.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
1–2 sprays
Target Dose
8–12 sprays/day
Timing
Titrate over 2 weeks
Best evidence for cancer pain. Prescription only in countries where approved.
Start Dose
2.5mg twice daily
Target Dose
5–10mg before chemotherapy
Timing
1–3 hours before chemotherapy
FDA-approved for CINV and anorexia. Prescription only.